These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 33136091)
1. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling. Cai W; Ni W; Jin Y; Li Y Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091 [TBL] [Abstract][Full Text] [Related]
2. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma. Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476 [TBL] [Abstract][Full Text] [Related]
3. [TRIP13 Enhances Radioresistance of Lung Adenocarcinoma Cells through the Homologous Recombination Pathway]. Ge S; Gu R; Yang X; Xu C; Wang S; Zhu G Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):1-12. PubMed ID: 38296621 [TBL] [Abstract][Full Text] [Related]
4. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway. Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942 [TBL] [Abstract][Full Text] [Related]
5. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition. Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167 [TBL] [Abstract][Full Text] [Related]
6. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816 [TBL] [Abstract][Full Text] [Related]
7. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma. Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway. Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074 [TBL] [Abstract][Full Text] [Related]
9. Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway. Liang J; Li H; Han J; Jiang J; Wang J; Li Y; Feng Z; Zhao R; Sun Z; Lv B; Tian H Cell Death Dis; 2020 Aug; 11(8):614. PubMed ID: 32792503 [TBL] [Abstract][Full Text] [Related]
10. TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells. Yu DC; Chen XY; Zhou HY; Yu DQ; Yu XL; Hu YC; Zhang RH; Zhang XB; Zhang K; Lin MQ; Gao XD; Guo TW Mol Biol Rep; 2022 Apr; 49(4):3055-3064. PubMed ID: 35032258 [TBL] [Abstract][Full Text] [Related]
11. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133 [TBL] [Abstract][Full Text] [Related]
13. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway. Zhou XY; Shu XM Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159 [TBL] [Abstract][Full Text] [Related]
14. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway. Zhu HE; Yin JY; Chen DX; He S; Chen H Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997 [TBL] [Abstract][Full Text] [Related]
15. C1orf74 positively regulates the EGFR/AKT/mTORC1 signaling in lung adenocarcinoma cells. Guo J; Li A; Guo R; He Q; Wu Y; Gou Y; Jin J; Huang G PeerJ; 2022; 10():e13908. PubMed ID: 36032960 [TBL] [Abstract][Full Text] [Related]
16. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling. Liu Z; Hu Z; Cai X; Liu S Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710 [TBL] [Abstract][Full Text] [Related]
17. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. Zhang G; Zhu Q; Fu G; Hou J; Hu X; Cao J; Peng W; Wang X; Chen F; Cui H Br J Cancer; 2019 Dec; 121(12):1069-1078. PubMed ID: 31740732 [TBL] [Abstract][Full Text] [Related]
18. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling. Shi Y; Xu Y; Yao J; Yan C; Su H; Zhang X; Chen E; Ying K J Cell Mol Med; 2021 Jul; 25(14):7013-7027. PubMed ID: 34121323 [TBL] [Abstract][Full Text] [Related]
19. PLEK2 activates the PI3K/AKT signaling pathway to drive lung adenocarcinoma progression by upregulating SPC25. Zhang W; Yu L; Xu C; Tang T; Cao J; Chen L; Pang X; Ren W Cell Biol Int; 2024 Sep; 48(9):1285-1300. PubMed ID: 38894536 [TBL] [Abstract][Full Text] [Related]
20. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. Agarwal S; Behring M; Kim HG; Chandrashekar DS; Chakravarthi BVSK; Gupta N; Bajpai P; Elkholy A; Al Diffalha S; Datta PK; Heslin MJ; Varambally S; Manne U Mol Oncol; 2020 Dec; 14(12):3007-3029. PubMed ID: 33037736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]